An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland
This study has been completed.
Sponsor:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Collaborator:
Alza Corporation, DE, USA
Information provided by:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
ClinicalTrials.gov Identifier:
NCT00236990
First received: October 7, 2005
Last updated: June 30, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and effectiveness of ELMIRON® in the treatment of chronic non-bacterial inflammation of the prostate gland.
| Condition | Intervention | Phase |
|---|---|---|
|
Prostatitis |
Drug: pentosan polysulfate sodium |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Double-Blind, Randomized, Placebo-Controlled Trial of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Prostatitis |
Resource links provided by NLM:
Further study details as provided by McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.:
Primary Outcome Measures:
- The change in total NIH-CPSI score from baseline to Week 12
Secondary Outcome Measures:
- Participant-reported Global Response Assessment at Week 12. Brief Male Sexual Function Index at Weeks 4, 8, and 12. Pelvic Pain Urgency and Frequency symptom scale at Weeks 4, 8, and 12.
| Enrollment: | 283 |
| Study Completion Date: | September 2005 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 001
pentosan polysulfate sodium
|
Drug: pentosan polysulfate sodium |
Detailed Description:
The objective of this randomized, double-blind, placebo-controlled study is to determine the effectiveness and safety of ELMIRON® 100 mg three times per day for 12 weeks, as compared with placebo, in patients with chronic non-bacterial inflammation of the prostate gland. Safety evaluations will be assessed throughout the study. The hypothesis of the study is that ELMIRON® will be more effective than placebo, as based on the change in the total National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score from baseline to the final visit (Week 12) and is generally well-tolerated. Patients will receive oral ELMIRON® 100 mg three times per day orally or matching placebo three times per day for 12 weeks.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of chronic non-bacterial prostatitis/chronic pelvic pain syndrome
- symptoms of discomfort or pain in the perineal and/or pelvic region (lower abdomen) for at least three of the last six months for which there is no recognized cause
- symptoms persist despite treatment with antibiotics for non-bacterial prostatitis in the past six months.
Exclusion Criteria:
- Clinically significant medical problems or other organ abnormalities
- psychiatric disorders
- urinary tract infection during the last three months
- history of bladder, urethral or prostate cancer
- Prostate Specific Antigen (PSA) greater than or equal to 4 ng/mL
- diagnosis or treatment for genital herpes or herpes flare within the last year.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00236990
Please refer to this study by its ClinicalTrials.gov identifier: NCT00236990
Sponsors and Collaborators
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Alza Corporation, DE, USA
Investigators
| Study Director: | McNeil Consumer & Specialty Pharmaceuticals, a Division of Mc Neil-PPC, Inc. Clinical Trial | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00236990 History of Changes |
| Other Study ID Numbers: | CR004687 |
| Study First Received: | October 7, 2005 |
| Last Updated: | June 30, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.:
|
prostatitis Elmiron pentosan polysulfate sodium |
Additional relevant MeSH terms:
|
Prostatitis Genital Diseases, Male Prostatic Diseases Pentosan Sulfuric Polyester |
Anticoagulants Hematologic Agents Pharmacologic Actions Therapeutic Uses |
ClinicalTrials.gov processed this record on March 03, 2015